Recce's R327 antibiotic showed strong results in reducing lung infections in early tests.

Recce Pharmaceuticals reported promising preclinical results for its antibiotic R327, showing near-complete bacterial reduction in a lung infection model, with strong lung tissue penetration and potential for direct delivery via inhalation. Imugene Ltd reported an 82% overall response rate in its Phase 1b trial of azer-cel, an off-the-shelf CAR-T therapy for relapsed or refractory diffuse large B-cell lymphoma, with 14 of 17 patients responding. The therapy targets CD19 and aims to activate the immune system against cancer. Meanwhile, the ASX faced a temporary system outage, and AUB Group fell after a takeover bid was withdrawn.